{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T15:36:47Z","timestamp":1767109007470,"version":"3.44.0"},"reference-count":11,"publisher":"BMJ","issue":"6","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2020,9,1]]},"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1136\/ejhpharm-2020-002418","type":"journal-article","created":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T17:25:12Z","timestamp":1599931512000},"page":"350-352","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Dramatic improvement of bullous pemphigoid with omalizumab in an elderly patient"],"prefix":"10.1136","volume":"28","clinical-trial-number":[{"clinical-trial-number":"nct00525616","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Francisco J","family":"Navarro-Trivi\u00f1o","sequence":"first","affiliation":[{"name":"Dermatology, Hospital Universitario San Cecilio, Granada, Andaluc\u00eda, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Maria","family":"Llamas-Molina","sequence":"additional","affiliation":[{"name":"Dermatology, Hospital Universitario San Cecilio, Granada, Andaluc\u00eda, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Ayen-Rodriguez","sequence":"additional","affiliation":[{"name":"Dermatology, Hospital Universitario San Cecilio, Granada, Andaluc\u00eda, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Cancela-D\u00edez","sequence":"additional","affiliation":[{"name":"Pharmacy, Hospital Universitario San Cecilio, Granada, Andaluc\u00eda, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0381-6174","authenticated-orcid":false,"given":"Ricardo","family":"Ruiz-Villaverde","sequence":"additional","affiliation":[{"name":"Dermatology, Hospital Universitario San Cecilio, Granada, Andaluc\u00eda, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,9,12]]},"reference":[{"key":"2025090502184042000_28.6.350.1","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12829","article-title":"Omalizumab as an alternative therapeutic tool in the treatment of bullous pemphigoid: a case report","volume":"32","author":"Vico-Alonso","year":"2019","journal-title":"Dermatol Ther"},{"key":"2025090502184042000_28.6.350.2","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jaad.2014.04.053","article-title":"Omalizumab therapy for bullous pemphigoid","volume":"71","author":"Yu","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"2025090502184042000_28.6.350.3","first-page":"251","article-title":"Role of IgE in bullous pemphigoid: a review and rationale for IgE directed therapies","volume":"147","author":"Messingham","year":"2012","journal-title":"G Ital Dermatol Venereol"},{"key":"2025090502184042000_28.6.350.4","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1111\/jdv.13758","article-title":"Successful treatment of bullous pemphigoid with omalizumab as corticosteroid-sparing agent: report of two cases and review of literature","volume":"30","author":"Balakirski","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025090502184042000_28.6.350.5","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jdcr.2020.01.002","article-title":"Increasing evidence for omalizumab in the treatment of bullous pemphigoid","volume":"6","author":"Lonowski","year":"2020","journal-title":"JAAD Case Rep"},{"key":"2025090502184042000_28.6.350.6","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s12016-015-8490-y","article-title":"Off-Label uses of omalizumab","volume":"50","author":"El-Qutob","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"2025090502184042000_28.6.350.7","first-page":"947","article-title":"Successful omalizumab therapy for bullous pemphigoid despite transient reaction","volume":"18","author":"Ewy","year":"2019","journal-title":"J Drugs Dermatol"},{"key":"2025090502184042000_28.6.350.8","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01919","article-title":"Effects of omalizumab on Fc\u03b5RI and IgE expression in lesional skin of bullous pemphigoid","volume":"10","author":"Seyed Jafari","year":"2019","journal-title":"Front Immunol"},{"key":"2025090502184042000_28.6.350.9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01918","article-title":"Learning from success and failure: biologics for non-approved skin diseases","volume":"10","author":"Speeckaert","year":"2019","journal-title":"Front Immunol"},{"key":"2025090502184042000_28.6.350.10","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-2-12"},{"key":"2025090502184042000_28.6.350.11","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13717"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2020-002418","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T09:18:47Z","timestamp":1757063927000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2020-002418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,12]]},"references-count":11,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,10,25]]},"published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1136\/ejhpharm-2020-002418"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2020-002418","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"type":"print","value":"2047-9956"},{"type":"electronic","value":"2047-9964"}],"subject":[],"published":{"date-parts":[[2020,9,12]]}}}